Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome

Leukemia Research

Volumn 35, Issue 1, 2011, Pages 136-

  Tabouret, Emeline ^a   Charbonnier, Aude ^a   Mozziconacci, Marie Joelle ^a   Ivanov, Vadim ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

FIP1L1 PDGFRA; Hypereosinophilic syndrome; Nilotinib

Indexed keywords

DESLORATADINE; FIP1L1 PROTEIN; IMATINIB; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROTEIN; QUININE BENZOATE; QUININE DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; CASE REPORT; CHROMOSOME DELETION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EOSINOPHILIA; GENE MUTATION; HUMAN; HYPEREOSINOPHILIC SYNDROME; LETTER; LIVER TOXICITY; LOW DRUG DOSE; MALE; MUSCLE DISEASE; PRIORITY JOURNAL; REMISSION; SPLENOMEGALY;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION;

EID: 78650176427     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.08.004     Document Type: Letter

References (3)

1. Ikezoe T., et al. Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 2010, 34(8):e200-e201.
2. Helbig G., et al. Weekly imatinib dosage for chronic eosinophilic leukaemia expressing FIP1L1-PDGFRA fusion transcript: extended follow-up. Br J Haematol 2009, 145(1):132-134.
3. Verstovsek S., et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res 2006, 30(12):1499-1505.